Inspire Medical Systems (NYSE:INSP) Price Target Lowered to $85.00 at Piper Sandler

Inspire Medical Systems (NYSE:INSP) had its price objective reduced by equities research analysts at Piper Sandler from $165.00 to $85.00 in a report issued on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Piper Sandler’s price target points to a potential upside of 24.10% from the stock’s previous close.

Other equities analysts have also recently issued reports about the stock. KeyCorp reissued a “sector weight” rating on shares of Inspire Medical Systems in a research note on Tuesday, November 4th. Zacks Research raised shares of Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a report on Monday, October 27th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $85.00 price objective (down previously from $160.00) on shares of Inspire Medical Systems in a report on Friday, October 24th. Wolfe Research upgraded Inspire Medical Systems from a “peer perform” rating to an “outperform” rating and set a $180.00 target price on the stock in a research report on Tuesday, November 25th. Finally, Mizuho raised their price target on Inspire Medical Systems from $110.00 to $130.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Six analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Inspire Medical Systems currently has an average rating of “Hold” and an average target price of $113.94.

Inspire Medical Systems Trading Up 0.5%

Shares of Inspire Medical Systems stock opened at $68.50 on Thursday. The company has a fifty day simple moving average of $96.03 and a 200-day simple moving average of $91.70. The stock has a market cap of $1.99 billion, a price-to-earnings ratio of 46.60, a PEG ratio of 6.87 and a beta of 0.74. Inspire Medical Systems has a 12-month low of $64.46 and a 12-month high of $197.75.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings data on Wednesday, February 11th. The company reported $1.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.96. The company had revenue of $269.08 million during the quarter, compared to analysts’ expectations of $264.02 million. Inspire Medical Systems had a return on equity of 9.41% and a net margin of 5.05%.The firm’s revenue for the quarter was up 12.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.15 earnings per share. On average, analysts forecast that Inspire Medical Systems will post 2.16 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Shawn Mccormick sold 2,000 shares of Inspire Medical Systems stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $127.48, for a total transaction of $254,960.00. Following the completion of the sale, the director directly owned 26,046 shares in the company, valued at $3,320,344.08. The trade was a 7.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 4.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Inspire Medical Systems

Several institutional investors and hedge funds have recently modified their holdings of the company. Manning & Napier Advisors LLC purchased a new stake in Inspire Medical Systems in the 3rd quarter worth approximately $32,000. CWM LLC lifted its stake in shares of Inspire Medical Systems by 216.1% during the 4th quarter. CWM LLC now owns 354 shares of the company’s stock worth $33,000 after purchasing an additional 242 shares during the period. Havemeyer Place LP acquired a new stake in shares of Inspire Medical Systems during the fourth quarter worth $39,000. V Square Quantitative Management LLC purchased a new stake in shares of Inspire Medical Systems in the fourth quarter valued at $40,000. Finally, Larson Financial Group LLC increased its stake in Inspire Medical Systems by 21,266.7% in the third quarter. Larson Financial Group LLC now owns 641 shares of the company’s stock valued at $48,000 after purchasing an additional 638 shares during the last quarter. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Key Stories Impacting Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q4 beat: EPS of $1.65 vs. Street ~$0.70 and revenue of $269.1M (+12% y/y), showing better-than-expected top- and bottom-line execution. Article Title
• Positive Sentiment: Strong full-year metrics and liquidity: 2025 revenue $912M (+14%), operating cash flow $117M, and $175M in share repurchases — supports cash generation and shareholder return capacity. Article Title
• Neutral Sentiment: Management commentary and detail available — full earnings-call transcript and slide deck provide color on Inspire V adoption, payer engagement and margin assumptions for 2026. Useful for modeling scenarios and hearing management’s mitigation plans. Article Title
• Negative Sentiment: Coding & reimbursement risk: Company said recent coding clarification points clinicians to CPT 64582 with a -52 modifier for Inspire V, which may lower physician reimbursement and slow procedure adoption; as a result management narrowed/revised 2026 revenue guidance to $950M–$1.0B (growth ~4%–10%), reflecting meaningful uncertainty. Article Title
• Negative Sentiment: Market reaction and positioning: Shares reportedly slid after the coding/guidance update (coverage noted a roughly 8% drop) and short interest rose materially in January to ~13.6% of float (up ~31%), increasing downside pressure and potential volatility. Article Title

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.